To learn more, go to Investments LLC decreased its stake in AerCap Holdings ( NYSE:AER – Get Rating) by 33.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. Guided by a world-renowned Scientific Advisory Council that includes four Nobel laureates and 24 members of the National Academy of Sciences, CRI has invested $420 million in support of research conducted by immunologists and tumor immunologists at the world’s leading medical centers and universities, and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment. The Cancer Research Institute (CRI), established in 1953, is the world’s leading nonprofit organization dedicated exclusively to saving more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. AER serves over 15,000 customers worldwide and its quality system is registered by Underwriters Laboratories (UL) to QS-9000 and ISO9001, ISO14001 and soon to be IATF 16949 standards.

With outstanding engineering expertise, state-of-the-art facilities, and excellent logistics, the company partners with some of the world’s outstanding automotive brands, including Ford, Chrysler, Nissan, GM, and Mitsubishi. In choosing to collaborate with the Cancer Research Institute, AER, its employees, and its customers are able to help more people affected by cancer across the world.įounded in 1947, AER is a privately-held automotive electronics remanufacturing firm, based in Southern California, providing premiere electronic component lifecycle support and extension to the global automotive market-manufacturers, OEM’s, and dealerships. Through its commitment to corporate social responsibility and being a leader in good corporate citizenship, AER demonstrates how companies and their employees have the power to create long-lasting social impact. “We are honored that AER has selected the Cancer Research Institute as its charity partner, and are grateful for both their financial support as well as AER’s help in raising awareness of the urgent need to fund laboratory and clinical research leading to better, immunotherapy-based treatment options for all cancer patients,” said Jill O’Donnell-Tormey, Ph.D., CEO and director of scientific affairs at CRI.

As our business grows, so does our financial commitment to helping others.” “AER believes it is our corporate responsibility to embrace helping those in need in researching a cure for this devastating disease. When our customers transact with AER, they help support our commitment to the Cancer Research Institute,” said Kim Quick, chief executive officer at AER. “AER is thankful for the opportunity to give back by both financially supporting the Cancer Research Institute and indirectly serving those in need. AER has committed to providing financial support in addition to raising awareness of immuno-oncology through shared digital resources and company-wide participation in CRI’s annual global awareness campaign, Cancer Immunotherapy Month.

NEW YORK and BREA, CA, Septem-The Cancer Research Institute (CRI) and AER Technologies have partnered to raise vitals funds for the advancement of cancer immunotherapy research.

Aer technologies